NCT00005606View on ClinicalTrials.gov

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 29, 2000

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

BIOLOGICAL

autologous Epstein-Barr virus-specific cytotoxic T lymphocytes

Trial Locations (1)

60611

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00005606 - Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation | Biotech Hunter | Biotech Hunter